UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/700/0.1/14.01.26

UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/700/0.1/14.01.26 Share Price

DE000HD29104

Real-time BOERSE MUENCHEN 01:10:52 20/05/2024 pm IST
1.58 ^EUR	0.00%

Current month	+97.50%
1 month	+49.06%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/700/0.1/14.01.26

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Jennifer Schneider Elected to Vertex Board of Directors	15/05	BU
Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director	15/05	CI
Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $520 From $497	14/05	MT
Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone	11/05	MT

More news

Quotes 5-day view

Date	Price	Change
20/24/20	1.58	0.00%
17/24/17	1.58	+9.72%
16/24/16	1.44	+2.13%
15/24/15	1.41	+16.53%
14/24/14	1.21	-6.20%

Real-time BOERSE MUENCHEN

Last update May 20, 2024 at 01:10 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	UniCredit
WKN	HD2910
ISIN	DE000HD29104
Date issued	29/01/2024
Strike	700 $
Maturity	14/01/2026 (605 Days)
Parity	10 : 1
Emission price	1.88 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	2.3 €
Lowest since issue	0.77 €
Delta	0.21x
Omega	5.528
Premium	61.11x
Gearing	25.74x
Moneyness	0.6360
Difference Strike	254.8 $
Difference Strike %	+36.40%
Spread	0.18 €
Spread %	10.71%
Theoretical value	1.600
Implied Volatility	29.32 %
Total Loss Probability	87.80 %
Intrinsic value	0.000000
Present value	1.600
Break even	717.40 €
Theta	-0.03x
Vega	0.15x
Rho	0.12x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

445.2 USD

Average target price

462.6 USD

Spread / Average Target

+3.90%

Consensus